DE60238780D1 - Depot formulierungen von iloperidone und einem sternförmigen polymer - Google Patents

Depot formulierungen von iloperidone und einem sternförmigen polymer

Info

Publication number
DE60238780D1
DE60238780D1 DE60238780T DE60238780T DE60238780D1 DE 60238780 D1 DE60238780 D1 DE 60238780D1 DE 60238780 T DE60238780 T DE 60238780T DE 60238780 T DE60238780 T DE 60238780T DE 60238780 D1 DE60238780 D1 DE 60238780D1
Authority
DE
Germany
Prior art keywords
iloperidone
star
depot formulations
term polymer
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60238780T
Other languages
English (en)
Inventor
Markus Ahlheim
Rolf Loeffler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH
Novartis AG
Original Assignee
Novartis Pharma GmbH
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma GmbH, Novartis AG filed Critical Novartis Pharma GmbH
Application granted granted Critical
Publication of DE60238780D1 publication Critical patent/DE60238780D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
DE60238780T 2001-10-30 2002-10-29 Depot formulierungen von iloperidone und einem sternförmigen polymer Expired - Lifetime DE60238780D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33903601P 2001-10-30 2001-10-30
PCT/EP2002/012073 WO2003037337A1 (en) 2001-10-30 2002-10-29 Depot formulations of iloperidone and a star polymer

Publications (1)

Publication Number Publication Date
DE60238780D1 true DE60238780D1 (de) 2011-02-10

Family

ID=23327202

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60238780T Expired - Lifetime DE60238780D1 (de) 2001-10-30 2002-10-29 Depot formulierungen von iloperidone und einem sternförmigen polymer

Country Status (12)

Country Link
US (2) US7767230B2 (de)
EP (2) EP1441727B1 (de)
JP (1) JP5067998B2 (de)
CN (2) CN1578664A (de)
AT (1) ATE493129T1 (de)
BR (1) BRPI0213564B8 (de)
CA (1) CA2463158C (de)
CY (1) CY1111357T1 (de)
DE (1) DE60238780D1 (de)
ES (2) ES2358416T3 (de)
HK (2) HK1068263A1 (de)
WO (1) WO2003037337A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4848113B2 (ja) * 1999-09-09 2011-12-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 血管新生血管に対するタキサンの陽イオン性リポソーム送達
CN1578664A (zh) * 2001-10-30 2005-02-09 诺瓦提斯公司 伊潘立酮和星状聚合物的贮库制剂
GB0216416D0 (en) * 2002-07-15 2002-08-21 Novartis Ag Organic compounds
CA3113166A1 (en) 2004-09-30 2006-04-13 Vanda Pharmaceuticals Inc. Methods for the administration of iloperidone
US20100063093A1 (en) * 2007-03-28 2010-03-11 Curt Wolfgang Methods for the administration of iloperidone
DE102005051342A1 (de) * 2005-10-25 2007-04-26 Goldschmidt Gmbh Verkapselung und kontrollierte Freisetzung biologisch aktiver Wirkstoffe mit enzymatisch abbaubaren hyperverzweigten Trägerpolymeren
PL1940905T3 (pl) 2005-10-25 2011-02-28 Evonik Degussa Gmbh Preparaty zawierające hiperrozgałęzione polimery
KR20090029200A (ko) 2006-05-22 2009-03-20 반다 파마슈티칼즈, 인코퍼레이티드. 우울증 질환에 대한 치료
CN100460441C (zh) * 2006-09-25 2009-02-11 南开大学 生物可降解星型结构聚乙丙交酯载药微球及其制备方法
EP2236546B1 (de) 2006-10-31 2011-12-28 Surmodics Pharmaceuticals, Inc. Kugelförmige Polymer-Partikel
WO2009036100A2 (en) * 2007-09-10 2009-03-19 Vanda Pharmaceuticals, Inc. Prediction of qt prolongation based on snp genotype
EP2222300B1 (de) 2007-12-13 2014-06-11 Vanda Pharmaceuticals Inc. Verfahren und zusammensetzung zur behandlung eines zustands, der durch den serotonin-rezeptor vermittelt wird
WO2009076663A1 (en) 2007-12-13 2009-06-18 Vanda Pharmaceuticals Inc. Method and composition for treating an alpha adrenoceptor-mediated condition
EP2453891A1 (de) 2009-07-16 2012-05-23 Vanda Pharmaceuticals Inc. Verwendung eines melatoninagonisten zur behandlung von schlafstörungen, u.a. primärer insomnie
BR112012015084A2 (pt) * 2009-12-23 2017-03-07 Lupin Ltd composição farmacêutica de liberação lenta de iloperidone
CN102311430A (zh) * 2010-06-29 2012-01-11 大道隆达（北京）医药科技发展有限公司 伊潘立酮的新晶态及其制备方法
WO2012123963A2 (en) * 2011-02-24 2012-09-20 Megafine Pharma (P) Ltd. A process for preparation of iloperidone and amorphous co- precipitate of iloperidone with pharmaceutically acceptable excipient
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
EP3620794A1 (de) 2012-01-26 2020-03-11 Vanda Pharmaceuticals Inc. Bestimmung der circadianen rhythmik
IN2014DN10691A (de) 2012-05-18 2015-08-28 Vanda Pharmaceuticals Inc
MX2015007909A (es) 2012-12-18 2016-04-25 Vanda Pharmaceuticals Inc Tratamiento de trastornos del ritmo circadiano.
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
CN103599074A (zh) * 2013-11-26 2014-02-26 重庆医药工业研究院有限责任公司 一种伊潘立酮缓释微球及其制备方法
CN104352443A (zh) * 2014-10-21 2015-02-18 河北科技大学 伊潘立酮缓释微球及其制备方法
CN116211857A (zh) 2015-02-17 2023-06-06 万达制药公司 用于治疗精神分裂症的伊潘立酮
US11071728B2 (en) 2015-12-11 2021-07-27 Vanda Pharmaceuticals Inc. Treatment of schizophrenia
MX2021006601A (es) * 2018-12-04 2021-07-07 Vanda Pharmaceuticals Inc Administracion de iloperidona de liberacion lenta.
US11607408B2 (en) 2019-10-15 2023-03-21 Vanda Pharmaceuticals Inc. Method of treatment of schizophrenia

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH656884A5 (de) * 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
DE3511587A1 (de) 1985-03-27 1986-10-02 Schering AG, Berlin und Bergkamen, 1000 Berlin Glykoester des estradiols und estriols
US4886370A (en) 1987-08-25 1989-12-12 Nkk Corporation Method for detecting a state of substance existing in pipe
ES2076253T3 (es) * 1989-05-19 1995-11-01 Hoechst Roussel Pharma N-(ariloxialquil)-heteroarilpiperidinas y -heteroarilpiperazinas, un procedimiento para su preparacion y su uso como medicamentos.
US5364866A (en) 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
US5776963A (en) 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
AU636043B2 (en) 1990-06-04 1993-04-08 Schering Corporation Method for preparing interferon alpha-2 crystals
NZ276088A (en) * 1993-11-19 1999-07-29 Janssen Pharmaceutica Nv [(1,2-benzisoxazol-3-yl)-1-piperidinyl-alkyl-6,7,8,9-tetrahydro-4h- pyrido[1,2-a]-pyrimidin-4-one derivatives (ie risperidone)
HUP0002106A3 (en) 1997-05-26 2001-11-28 Akzo Nobel Nv Aromatic sulfonates of trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1h-dibenz-[2,3:6,7]oxepino[4,5-c]pyrrole and pharmaceutical compositions containing it
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
DE19816070A1 (de) 1998-04-09 1999-10-14 Aventis Res & Tech Gmbh & Co Retardtablette hergestellt aus linearen wasserunlöslichen Polysacchariden
KR20010072878A (ko) * 1998-10-16 2001-07-31 디르크 반테 인식을 개선하기 위한 아세틸콜린에스테라제 억제제와배합된 비정형 항정신병제
JP2003535106A (ja) 2000-06-02 2003-11-25 ノボ ノルディスク アクティーゼルスカブ グルコース検知性インスリン誘導体からの、インスリンのグルコース依存性放出
US20050020632A1 (en) 2001-08-31 2005-01-27 Dominique Grimler Optical isomers of an iloperidone metabolite
CN1578664A (zh) * 2001-10-30 2005-02-09 诺瓦提斯公司 伊潘立酮和星状聚合物的贮库制剂
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
ATE493129T1 (de) 2011-01-15
US20100233217A1 (en) 2010-09-16
HK1155381A1 (en) 2012-05-18
CN101912367A (zh) 2010-12-15
CN1578664A (zh) 2005-02-09
JP5067998B2 (ja) 2012-11-07
ES2436439T3 (es) 2014-01-02
ES2358416T3 (es) 2011-05-10
CA2463158A1 (en) 2003-05-08
EP2295058B1 (de) 2013-09-04
WO2003037337A8 (en) 2004-05-13
BR0213564A (pt) 2004-08-31
EP1441727B1 (de) 2010-12-29
CY1111357T1 (el) 2015-08-05
CA2463158C (en) 2013-07-30
JP2005508975A (ja) 2005-04-07
US8815293B2 (en) 2014-08-26
EP1441727A1 (de) 2004-08-04
EP2295058A1 (de) 2011-03-16
BRPI0213564B1 (pt) 2016-08-02
WO2003037337A1 (en) 2003-05-08
BRPI0213564B8 (pt) 2021-05-25
US7767230B2 (en) 2010-08-03
US20030091645A1 (en) 2003-05-15
HK1068263A1 (en) 2005-04-29

Similar Documents

Publication Publication Date Title
DE60238780D1 (de) Depot formulierungen von iloperidone und einem sternförmigen polymer
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
DE69812946D1 (de) Ethylenpolymerzusammensetzungen und daraus hergestellte gegenstände
DE69902913D1 (de) Injizierbare zweiphasige zusammensetzungen für kosmetische und plastische chirurgie
DE60144375D1 (de) 7-, 8- und 9-substitutierte tetracyclinverbindungen
ATE296642T1 (de) Reverse-phase zusamensetzung zur bindegewebsreparatur
DE69923359D1 (de) Zusammensetzungen und daraus hergestellte gegenstände
DE60137039D1 (de) Verschiebung von verschlüssen zur herstellung von windeln
DE60110292D1 (de) Polymer und Photoresistzusammensetzungen
BR9811000A (pt) "composições poliméricas"
AU2001259651A1 (en) Polymers containing oxygen and sulfur alicyclic units and photoresist compositions comprising same
DE60012176D1 (de) Polymerisation von fluoropolymeren
DE69626589D1 (de) Polymer, Verfahren zur Herstellung, Haarbehandlungszusammensetzungen und kosmetische Zusammensetzungen
DE60235579D1 (de) Fotochromische polymerzusammensetzungen und artikel daraus
ID15948A (id) Komposisi-komposisi insektisida berdasarkan polimer-polimer
BR9400436A (pt) Polímero, sutura e artigo cirúrgico
NO20024891D0 (no) Farmasöytiske sammensetninger
ATE404605T1 (de) Funktionalisierte alkydpolyesterpolymere zur medizinischen verwendung
IS7217A (is) Leysnistýrðar fjölliðasamsetningar af beinvaxtamótunar efnasamböndum
DE60214853D1 (de) Biologisch abbaubare kaugummigrundmasse
DE69132415T2 (de) Umweltfreundliche Polymerzusammensetzungen sowie Anwendungen desselben
DE19882607T1 (de) Verfahren zur Herstellung von Olefinpolymeren oder -copolymeren sowie Olefinpolymere oder -copolymere und Anwendungen davon
DE60120416D1 (de) Polyaminoestern und deren verwendung zur herstellung von dentalmassen
DE60234756D1 (de) Konjugierte homo- und copolymere enthaltend substituierte oder unsubstituierte heteroaryleinheiten, herstellung und verwendung
DE69901023D1 (de) Knochenimplantat